Cenerimod
Cenerimod is an active Lysosphingolipid receptor agonist originated by Actelion Pharmaceuticals and EC50 value is 2.7 nM. It is a S1P1/EDG1 receptor agonist and has a long-lasting immunomodulating effect through reducing the number of circulating and infiltrating T- and B-lymphocytes, without affecting their maturation, memory, or expansion. Cenerimod is in phase I/II clinical trials for the treatment of Systemic lupus erythematosus.
| Supplier | BOC Sciences |
|---|---|
| Product # | 1262414-04-9 |
| Pricing | Inquire |
| Cas | 1262414-04-9 |
| Molecular Weight | 453.54 |
| Molecular Formula | C25H31N3O5 |
| Canonical SMILES | CCc1cc(cc(c1OC[C@H](CO)O)C)c2nc(on2)c3cc(nc(c3)OC)C4CCCC4 |